Trial Profile
A study in an outpatients with metastatic breast cancer switching from intravenous pamidronate to subcutaneous denosumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Pamidronic acid
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Dec 2015 New trial record